Drug Profile
Research programme: nSMASE inhibitors - Lpath
Alternative Names: neutral sphingomyelinase inhibitors - LpathLatest Information Update: 27 Apr 2011
Price :
$50
*
At a glance
- Originator Lpath
- Class
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Cerebrovascular disorders
Most Recent Events
- 23 Jan 2007 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
- 23 Jan 2007 Preclinical trials in Cerebrovascular disorders in USA (unspecified route)